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Abstract 
Changes in phosphate-activated glutaminase activities determined in intact cells and isolated mitochondria have been followed during mouse 
Ehrlich ascites carcinoma development. Glutaminase activities parallel the levels of poly(A)’ RNAs encoding for the mitochondrial phosphate 
activated glutaminase. During the exponential growth phase, maximum activity was observed and the relative abundance of glutaminase mRNA 
significantly increased with regard to the stationary growth phase. The presented results show that tumor phosphate-activated glutaminase is subject 
to long-term regulation by differential gene expression. 
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1. Introduction 
Glutamine is avidly consumed by rapidly dividing cells 
[ 11; in fact, glutamine is a good respiratory substrate and 
a source for nitrogen compounds (for reviews see [2,3]). 
The first step in glutaminolysis is that catalysed by phos- 
phate-activated glutaminase (PAG) (EC 3.5.1.2), a mito- 
chondrial enzyme [4]. An enzymic imbalance in the glu- 
tamine-related enzymes occurs in tumor cells. In human 
hepatocellular carcinoma, glutamine synthetase activity 
(EC 6.3.1.2) is one-third of that in normal liver, whereas 
PAG increases approximtely 20-fold [5]. Indeed, PAG 
activity is correlated with malignancy [6] in tumors and 
with growth rate in normal cells, e.g. thymocytes [7]. In 
human diploid fibroblast cultures, Sevdelian et al. [8] 
reported that the capacity to hydrolysing glutamine 
reaches a maximum after 2 days of growth and this 
activity is independent of the glutamine concentration in 
the culture medium. 
PAG is present in different mammalian tissues: mostly 
in brain, liver, kidney and enterocytes [9]. Two isozymes 
have been described: liver type and kidney type [9]. In 
spite of the main role of glutamine metabolism in tumors 
[2,3], studies on PAG in tumors are scarce. Quesada et 
al. [lo] concluded by analysis of kinetic behaviour and 
immunoblot analysis that Ehrlich ascitic tumor PAG is 
a kidney type enzyme. Very recently, Curthoys’ group 
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Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
PAG, phosphate-activated glutaminase; SDS, sodium dodecyl 
sulphate. 
[l l] reported a long-term regulation for rat kidney PAG 
during metabolic acidosis; in the same way, Smith and 
Watford [ 121 reported that liver PAG mRNA increase 
4-fold in diabetic rats. 
In this study, changes in hydrolysing glutamine capac- 
ity of intact cells and isolated mitochondria, as well as 
changes in phosphate-activated glutaminase mRNA lev- 
els, were followed during tumor development; a long- 
term regulation for tumor PAG expression was deduced. 
2. Materials and methods 
2. I. Ehrlich cells and animal treatments 
A hyper-diploid LettrC strain of Ehrlich carcinoma was maintained 
as described elsewhere [13]. Animals were sacrificed on different days 
after tumor transplantation by cervical dislocation. Immediately there- 
after, cells were separated by centrifugation at 900 x g for 5 min. 
2.2. Phosphate-activated glutaminase assay in intact cells and isolated 
mitochondria 
Harvested cells were washed three times with 0.1 M Tris-HCl, pH 
8, and suspended in the same buffer for 3 h in order to deplete en- 
dogenous substrates. Mitochondria were isolated as previously de- 
scribed [14]. The reaction medium was: 0.1 M Tris-HCl, pH 8, 0.2 M 
potassium phosphate, 20 mM glutamine, 20 &ml oligomycin and 1.2 
&ml antimycin A to prevent glutamate oxidation. Under these condi- 
tions glutamine and phosphate are at saturating concentrations [lo]. 
For assays in intact cells, 0.2 ml of cell suspension, equivalent to 
40 x lo6 cells, was used; after 6 min of incubation at 37°C the reaction 
was stopped by the addition of 0.5 ml of 0.4 N HCl. For assays in 
isolated mitochondria, about 50 pg of total protein were used with 10 
min of incubation. The KOH-neutralized mixture was centrifuged at 
16,000 x g during 5 min. Finally, the glutamate formed was determined 
according to Lund [I 51. To ensure PAG was indeed the enzyme assayed, 
the results of controls without phosphate were always substracted [16]. 
Blanks with sample omitted were also run in parallel. Ehrlich ascites 
tumor cells and isolated mitochondria were counted with a Coulter 
Counter ZM (England). Protein concentrations were determined using 
a modified Lowry procedure [17]. 
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2.3. RNA isolation and blot hybrydization analysis 
PAG mRNA levels were determined by Northern blot analyses. 
Total RNA from Ehrlich ascites tumor cells was isolated as described 
by Chomczynski and Sacchi [18]. The poly(A)’ RNA fraction was 
enriched using the Fasttrack mRNA isolation kit from Invitrogen (San 
Diego, CA, USA). RNAs were fractionated on 1.5% agarose gels con- 
taining 0.8 M formaldehyde, transferred onto positively charged Nylon 
membranes (Boehringer, Mannheim, Germany), and then hybridized 
to the cDNA that corresponds to the coding sequence of rat kidney 
phosphate-activated glutaminase gene [19], kindly supplied by Prof. 
N.P. Curthoys (Colorado State University, USA). The cDNA was 
labelled using the Megaprime DNA labelling system with [a-32P]dCTP 
(Amersham Ibtrica, Spain). Hybridization was carried out at 42°C in 
50% formamide, 5 x SSPE, 5 x Denhardt’s and 2Oj@ml of denaturated 
salmon sperm DNA for 1624 h. The membranes were successively 
washed for 20 min at 60°C with 2 x, 0.5 x, and 0.1 x. SSC containing 
0.1% SDS. Kodak X-OMAT AR films were exposed to the blots at 
-80°C with intensifying screens for 7-14 days. As an internal standard, 
the mRNA for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was detected, using a 1.3 kb GAPDH cDNA [20]. Autoradiograms were 
analyzed by transmitance densitometry, using a Hoefer GS 300 scan- 
ning densitometer (Hoefer Scientific, USA). 
3. Results and discussion 
Fig. 1 shows the capacity of intact Ehrlich ascites car- 
cinoma cells for hydrolysing glutamine throughout 
tumor development. The results, expressed as either per 
mg of protein or per cell number, indicated that PAG is 
more active during the exponential phase of growth, with 
a subsequent decrease when the cells reach the stationary 
growth phase (Fig. 1 and Fig. 2A). It is noteworthy that 
even in tumor cells harvested in the stationary phase of 
growth, the glutamine-hydrolysing capacity is very high 
[21]. Increased specific activities of other glutamine-util- 
izing enzymes, particularly those involved in pyrimidine 
and purine biosynthesis, have also been described in ex- 
perimental and human tumors [22]. Since in our experi- 
ments the glutamate formed in the absence of phosphate 
was always subtracted, the hydrolysis of glutamine in- 
Days after tumor transplantation 
Table 1 
Total protein content of intact cells and mitochondria during Ehrlich 
ascites carcinoma development 
Days after tumor transplantation 
4 7 9 11 14 
Cell 100 17.6+ 1.3 73.0f 1.3 72.0 + 5.2 82.2+ 6.6 
Mitochondria 100 76.0 f 3.2 N.D. 36.0 f 2.7 46.9 + 1.3 
Values at day 4 (152 f 10 pg protein/lo6 cells and 2.1 f 0.1 pg protein/ 
lo6 mitochondria) are given as 100%. Values are means f S.E.M. of 
three different determinations. Cells and mitochondria were counted 
and total protein determined as described in section 2. N.D., not deter- 
mined. 
deed reflects the phosphate-activated glutaminase reac- 
tion which is the first step in glutamine catabolism. Fur- 
thermore, the ‘phosphate-independent’ glutaminase ac- 
tivity was only appreciable in whole depleted cells, being 
negligible in isolated mitochondria (results not shown). 
Phosphate-activated glutaminase has been described 
as a mitochondrial enzyme [4]; a similar profile to that 
showed for intact cells was obtained when PAG was 
assayed using isolated tumor mitochondria (Fig. 2B). 
Maximum activity was found in mitochondria isolated 
from cells in the exponential phase of growth and the 
activity decreased in mitochondria isolated from cells in 
the stationary phase of growth. The PAG activity was 
expressed as specific activity based on total protein con- 
tent of mitochondria. In order to assess whether this 
observed decrease in PAG activity corresponds to a real 
change in the mitochondrial PAG enzyme, or whether it 
is the result of a protein change in the cell or in the 
mitochondria, total protein content was measured in 
both intact cells and mitochondria throughout tumor 
development. Table 1 shows that the total protein con- 
tent decreased both in intact cells and isolated mitochon- 
Days after tumor transplantation 
Fig. 1. Phosphate-activated glutaminase activities of intact Ehrlich ascites carcinoma cells during tumor development. Controls with phosphate 
omitted were always subtracted, as described in section 2. Values in mU (nmol/min) per mg of total protein (A) or per lo6 cells (B) are the means 
of at least three different experiments f S.E.M. 
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Days after tumor tronsplontction Days after tumor transplantation 
Fig. 2. (A) Growth curve for Ehrlich ascites carcinoma cells after the inoculation of 5 x lo6 cells (taken from [24]). (B) Phosphate-activated glutaminase 
activity in isolated mitochondria from Ehrlich cells at different days after tumor transplantation. Values are means of at least three different duplicate 
exper&nts f S.E.M. 
dria from the 4th day after tumor transplantation. The 
results confirm that a real decrease in the PAG activity 
occurs when cell proliferation stops. 
By only measuring activity, even in isolated mitochon- 
dria, it is not possible to establish a long-term regulation 
of PAG during tumor development unless a parallel in- 
crease in the respective mRNA levels is confirmed. Thus, 
the cell PAG mRNA levels at different days of tumor 
development should be analyzed. Autoradiograms of 
blot hybridization analyses of poly(A)’ RNA were stan- 
dardized with mRNA of glyceraldehyde-3-phosphate de- 
hydrogenase, using a GAPDH cDNA rehybridized in 
the same filter (Fig. 3). A significant increase in PAG 
mRNA was obtained on the 7th day as compared with 
the mRNA of the 1 lth day. The profile of mRNA levels 
at different days throughout tumor development paral- 
lels the PAG activity; it seems that the expression of PAG 
is roughly correlated to the specific PAG activity. From 
its relative electrophoretic mobility, the size of the Ehrl- 
ich ascitic tumor glutaminase mRNA was estimated to 
be approximately 7.0 kb (Fig. 3). A very weak minor 
band corresponding to a mRNA of 3.4 kb was also 
detected. The relative sizes of tumor glutaminase 
mRNAs are in good agreement with those reported for 
rat kidney by Hwang et al. [23], who also observed two 
bands of 6.0 and 3.4 kb with the 6.0 kb band as the most 
prominent. 
The presented results indicate that expression of phos- 
phate-activated glutaminase, the first enzyme of the glu- 
taminolytic process, is subject to long-term regulation 
during tumor development. In vivo, glutamine is sup- 
plied by the host tissues, namely liver, kidney and muscle 
[24]. Carrascosa et al. [21] reported that tumors elicit a 
specific response in the host nitrogen metabolism so that 
the whole organism is mobilized to increase circulating 
glutamine. This amino acid is avidly consumed by the 
tumor in such a way that, on the 7th day following tumor 
transplantion, glutamine was found neither in the ascitic 
liquid, the natural medium of Ehrlich carcinoma growth, 
nor in the cells [25]. Thus, a positive gradient from host 
plasma to tumor cells is created. In this context, glutam- 
inase could be considered the main pathway for nitrogen 
trapping by tumors. Although PAG activity is elevated 
in transformed cells, maximum expression occurs when 
the cells are actively dividing during the exponential 
phase of growth, coincident with the maximum nitrogen 
requirement. 
Tumor cells apparently waste glucose and glutamine, 
since malignant tumors overcome their own needs. A 
continuous output of the end products, lactate, gluta- 
mate and ammonia, conform that tumor behaves as a 
powerful dissipative system. Crabtree and Newsholme 
[ 1,261 have theoretically justified the wasteful spreading 
of energy and nitrogen in very rapidly growing cells: a 
high rate of glutaminolysis is needed, not only for pre- 
cursor provision per se, but for the sensitivity of the 
pathways involved in the biosynthetic processes; our re- 
Daya after tumor transDlantation 
PAG 
GAPDH 
Fig. 3. Northern blot analysis of poly(A)’ RNA from Ehrlich tumor 
cells growing ‘in vivo’ at different days after tumor inoculation. 32P- 
labeled cDNA from rat kidney PAG was used as a probe. Experimental 
conditions are explained in section 2. The signal for control mRNA 
(GAPDH) is shown below the PAG autoradiogram, and it was ob- 
tained by rehybridization of the same filter. 
42 
sults seem to support this hypothesis. The experimental 
evidence here presented links the activity increase with 
a significant increase in the relative mRNA levels. The 
mechanisms responsible for the long-term regulation of 
tumor PAG will require further characterization; how- 
ever, the results now reported will lead to a better under- 
standing of the role of this key enzyme in neoplastic 
transformation. 
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